The approval itself was increasingly expected, not a binary surprise. The FDA accepted the daraxonrasib application for review on July 22, 2026, after the positive RASolute 302 Phase 3 readout, and Revolution Medicines said on August 5 that it had achieved U.S. commercial launch readiness. That makes this primarily a timing-and-execution update rather than a fresh clinical validation event.
The filing converts the lead asset from a development program into an approved product. The FDA approved RASONQUE for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or for patients who are not candidates for multiagent therapy. 〔0〕
The timing is better than the standing setup, while the core approval thesis was already largely in view. The FDA described the action as arriving months ahead of schedule, which is the clearest incremental positive in this filing versus expectations. The company can now begin generating commercial evidence rather than relying solely on trial-based valuation.
The immediate commercial facts are clear, but revenue expectations will depend on access and uptake. RASONQUE is available for U.S. prescribing now, with a wholesale acquisition cost of $39,800 for a 30-day supply. 〔1〕 The filing does not provide launch guidance, payer coverage detail, or a sales forecast, so the net read is a modest positive regulatory surprise—not yet proof of commercial performance.
Read the original 8-K on SEC EDGAR ↗